AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive Bladder Cancer Trial
AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with ...
ESMO 2024: Imfinzi to be practice changing in perioperative bladder cancer setting
The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.
The Pharma Letter5d
ESMO 2024: Imfinzi NIAGARA Phase III trial success in bladder cancer
Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) ...
AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...
Cure Today7d
Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.
FiercePharma5d
ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...